РОБИНСОН Дэниел (US),ПЭК Джеймс (US),САМУЭЛЬСОН Гари (US)
申请号：
RU2015114716
公开号：
RU2015114716A
申请日:
2013.02.28
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A composition comprising at least one redox signaling molecule (RXN) and agonist PPAR.2. Composition according to claim. 1, in which the PPAR agonist is a free fatty acid (FFA) .3. Composition according to Claim. 1, wherein the PPAR agonist is eykozanoid.4. Composition according to Claim. 1, wherein the PPAR agonist is tiazolidindion.5. Composition according to Claim. 1, wherein the PPAR agonist is fibrat.6. Composition according to Claim. 1, wherein the PPAR agonist is a double agonist.7. A composition according to claim. 6, wherein the dual agonist is aleglitazar.8. A composition according to claim. 6, wherein the dual agonist is muraglitazar.9. A composition according to claim. 6, wherein the dual agonist is tezaglitazar.10. Use of a composition comprising a PPAR agonist and RXN, in the treatment of PPAR mediated zabolevaniya.11. The use of claim. 10 wherein the disease mediated by PPAR is a sugar diabet.12. The use of claim. 11 wherein the diabetes is type 1 diabetes tipa.13. The use of claim. 11 wherein the diabetes is diabetes tipa.14 2. The use of claim. 10 wherein the disease mediated by PPAR is ozhirenie.15. The use of claim. 10 wherein the disease mediated by PPAR is rak.16. Use of a composition comprising at least one RXN, in treating cancer, including a first therapeutic agent, activating the path PPAR, and at least one other agent that does not activate the path PPAR.17. The use of claim. 16 wherein the at least one other agent is a obluchenie.18. The use of claim. 16 wherein the at least one other agent is a chemotherapeutic sredstvo.19. Use of a composition comprising at least one RXN, the treatment of cancer,1. Композиция, содержащая по меньшей мере одну окислительно-восстановительную сигнальную молекулу (RXN) и агонист PPAR.2. Композиция по п. 1, в которой агонист PPAR представляет собой свободную жирную кислоту (FFA).3. Композиция по п. 1, в которой агонист PPAR представляет собой эйкозаноид.4. Композиция по п. 1, в которой агонист PPAR представ
